SPRO

Business Context and Reporting Period

Spero Therapeutics, Inc. (SPRO) is a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for immune-mediated diseases. This Form 10-Q covers the quarterly period ended June 30, 2026. The Company recently shifted its strategic focus following the FDA approval of its partner GSK's NDA for Utebzi (tebipenem pivoxil) in June 2026. Spero has terminated its earlier-stage programs (SPR206 and SPR720) and is now prioritizing the development of SP001, a monoclonal antibody targeting CD40L, following a new exclusive license agreement with Innovent Biologics entered into in July 2026.

Key Financial Metrics

Note: The filing does not provide explicit gross margin or operating margin percentages due to the absence of product sales revenue.

Material Changes vs. Prior Period

• Revenue Decline: Total revenues dropped to $0 for the three months ended June 30, 2026, compared to $14.2 million in the same period in 2025. This decrease is primarily due to the cessation of grant revenue from the BARDA contract (terminated July 2026) and the completion of revenue recognition for development milestones under the GSK License Agreement.
• Expense Reduction: Total operating expenses decreased by approximately 40% year-over-year for the three-month period ($9.9 million vs. $16.6 million). Research and Development (R&D) expenses fell significantly ($3.4 million vs. $10.7 million) due to the conclusion of the pivotal Phase 3 PIVOT-PO trial for Utebzi and the termination of the SPR720 program.
• Cash Flow Improvement: Net cash provided by operating activities turned positive at $10.5 million for the six months ended June 30, 2026, compared to a use of $21.7 million in the prior year. This was driven by the collection of a $25.4 million collaboration receivable from GSK related to the NDA resubmission milestone.
• Balance Sheet: Cash and cash equivalents increased to $50.8 million from $40.3 million at year-end 2025. Total assets decreased to $52.8 million from $68.9 million, largely due to the collection of the collaboration receivable.

Guidance, Outlook, and Risks

• Strategic Pivot: Management has shifted resources to SP001. The Company expects to file a U.S. IND for SP001 within 12 months of the July 2026 Innovent agreement and advance to a Phase 2 trial in IgG4-RD patients in Q2 2027.
• Liquidity Outlook: Management believes that existing cash ($50.8 million) combined with net proceeds from a $105 million royalty financing transaction with HCRx (closed July 2026) will fund operations into the second half of 2029. The Company expects to incur significant operating losses for the foreseeable future.
• Subsequent Events:
  • Innovent Agreement: Entered into an exclusive license for SP001 requiring a $35 million upfront payment and potential milestones up to $1.05 billion.
  • Royalty Financing: Sold 65% of future GSK proceeds (milestones and royalties) to HCRx in exchange for $105 million in notes and a cash payment, retaining 35% of proceeds after note repayment.
• Risks:
  • Dependency: Future success is heavily dependent on the commercialization of Utebzi by GSK and the development of SP001.
  • Regulatory: Uncertainty regarding FDA acceptance of foreign clinical trial data (specifically Innovent's Phase 1b data from China) for the SP001 IND.
  • Legal: The SEC concluded its investigation into the Company in January 2026 without recommending enforcement action, though former executives faced cease-and-desist orders.

Investor Verification Checklist

• SP001 Timeline: Verify the Company's ability to file the U.S. IND for SP001 within the required 12-month window and the FDA's acceptance of foreign clinical data.
• Utebzi Commercialization: Monitor GSK's launch and sales performance of Utebzi, as Spero's future royalty income (35% share) depends entirely on this.
• Cash Burn Rate: Assess the impact of the $35 million upfront payment to Innovent on the projected runway into late 2029.
• Royalty Financing Terms: Review the specific triggers for the $105 million HCRx notes and the impact of the 65% royalty sale on long-term upside potential.
• SEC Investigation Closure: Confirm that no further legal liabilities remain from the concluded SEC investigation regarding 2022 disclosures.